Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
|Articles|January 1, 1998
Supplements and Featured Publications
- A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
- Volume 4
- Issue 1 Suppl
Chronic Ambulatory Outpatients and Four-Vector Management
Author(s)Richard Petty, MD
Advertisement
Articles in this issue
almost 29 years ago
Common Treatment Goals: Switching Antipsychoticsalmost 29 years ago
Antipsychotics : Present and Futurealmost 29 years ago
Atypical Antipsychotics in the Managed Care Eraalmost 29 years ago
CME Quizalmost 29 years ago
Selected Abstractsalmost 29 years ago
Bibliographyalmost 29 years ago
Participating Facultyalmost 29 years ago
Introduction - The Routine Use of Atypical Antipsychoticsalmost 29 years ago
Atypical Antipsychotics and Formulary DecisionsAdvertisement
Related to this article
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5